TRCT
FURX

Tower Research Capital (TRC)’s FURIEX PHARMACEUTICALS INC COM STK (DE) FURX Stock Holding History

Tower Research Capital (TRC)’s Portfolio FURX Stock Details FURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-401
Closed -$35K – 5296
2014
Q1 		$35K Buy
401
+305
+318% +$23.5K ﹤0.01% 1365
2013
Q4 		$4K Sell
96
-888
-90% -$36.5K ﹤0.01% 3786
2013
Q3 		$44K Buy
+984
New +$40.7K ﹤0.01% 2036

Other funds holding FURX

D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Tower Research Capital (TRC)'s FURX Position: Q2 2014 in Review

Tower Research Capital (TRC) sold out of FURIEX PHARMACEUTICALS INC COM STK (DE) (FURX) in Q2 2014, closing a stake of 401 shares — an estimated $35K sold.

Tower Research Capital (TRC) first reported a position in FURX in Q3 2013 and held it in 3 quarters. The position peaked at $44K in Q3 2013. 102 funds tracked by Wall St. Rank hold FURX as of Q2 2014.

  • Tower Research Capital (TRC) reported no remaining FURIEX PHARMACEUTICALS INC COM STK (DE) position as of Q2 2014 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 401 FURIEX PHARMACEUTICALS INC COM STK (DE) shares in Q2 2014, an estimated $35K.
  • Tower Research Capital (TRC) first reported a position in FURIEX PHARMACEUTICALS INC COM STK (DE) in Q3 2013 and held it in 3 quarters.
  • Tower Research Capital (TRC)'s FURIEX PHARMACEUTICALS INC COM STK (DE) position peaked at $44K in Q3 2013.
  • 102 funds tracked by Wall St. Rank held FURIEX PHARMACEUTICALS INC COM STK (DE) as of Q2 2014.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2014, filed 14 Aug 2014.